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a b s t r a c t
This paper describes computer-aided design of new anti-viral agents against Vaccinia virus (VACV) poten-
tially acting as nucleic acid intercalators. Earlier obtained experimental data for DNA intercalation affini-
ties and activities against Vesicular stomatitis virus (VSV) have been used to build, respectively,
pharmacophore and QSAR models. These models were used for virtual screening of a database of 245
molecules generated around typical scaffolds of known DNA intercalators. This resulted in 12 hits which
then were synthesized and tested for antiviral activity against VaV together with 43 compounds earlier
studied against VSV. Two compounds displaying high antiviral activity against VaV and low cytotoxicity
were selected for further antiviral activity investigations.
 2017 Elsevier Ltd. All rights reserved.
Introduction
Viral diseases have a severe negative impact on human life
worldwide1,2 whichmotivates researchers to develop new antiviral
drugs. Most of known target-specific antiviral compounds inhibit
certain viral proteins, e.g. protease or polymerase.3 Such com-
pounds are rather selective, have low toxicity and the reduced risk
of adverse effects. Corresponding drug discovery projects are fre-
quently supported by different chemoinformatics tools. Thus, a
combination of QSAR and docking methods were used to identify
a novel influenza virus neuraminidase inhibitor which is more
potent than the commercialized drug Oseltamivir.4 The virtual
screening procedure involving similarity search, shape-based and
pharmacophore models was used to discover HIV-1 reverse tran-
scriptase dual inhibitors.5
Broad spectrum antiviral agents may, however, be more advan-
tageous than target-specific compounds in controlling multiple
emerging pathogens.6 There exist several major groups of broad-
spectrum antivirals. One of them includes interferon and inter-
feron inducers. Interferon is a protein produced as an immune
response, inducing synthesis of protein kinase which phosphory-
lates initiation factor of translation and, therefore, prevents syn-
thesis of viral proteins. The second group includes nucleotide
analogs, i.e., substances which resemble DNA or RNA nucleotide
but have an inappropriate nitrogenous base. Being captured by
proteins or tRNA involved in the virus reproduction processes, they
may lead to the synthesis of a non-coding sequences in viral
nucleic acids.7 The third group includes nucleic acid intercalators
which may entry between the parallel pairs of bases in double
helix of DNA or RNA.8 To our knowledge, in silico approaches are
rarely used in the design of broad spectrum antivirals and no com-
puter-aided design of intercalators was reported so far.
In this study, we performed ligand-based virtual screening of
new promising nucleic acid intercalators using Quantitative Struc-
ture-Activity Relationships (QSAR) and pharmacophore models.
Selected hits were synthesized and tested experimentally against
Vaccinia virus (VACV), which is a double-stranded DNA virus of
the Poxviridae family similar to potential biothreat variola virus.
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